Charles‐Édouard Luyt

Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial

Lila Bouadma, Charles‐Édouard Luyt, Florence Tubach et al. · The Lancet · 2010 · 1.1K citations

Critical Care Medicine, Intensive Care Units, Antimicrobial Stewardship +9

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin, Alexis Mathian, Makoto Miyara et al. · Science Translational Medicine · 2020 · 1.1K citations · Full text

Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock*

Alain Combes, Pascal Leprince, Charles‐Édouard Luyt et al. · Critical Care Medicine · 2008 · 636 citations

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Paul Bastard, Adrian Gervais, Tom Le Voyer et al. · Science Immunology · 2021 · 600 citations · Full text

The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Matthieu Schmidt, Élie Zogheib, Hadrien Rozé et al. · Intensive Care Medicine · 2013 · 556 citations · Full text

Acute Lung Injury, Medicine, Acute Care +6